EXEL
USDExelixis Inc. Common Stock
Echtzeitkurs
Kursdiagramm
Schlüsselkennzahlen
Marktkennzahlen
Eröffnung
$37.810
Hoch
$38.900
Tief
$37.582
Volumen
2.81M
Unternehmensfundamentaldaten
Marktkapitalisierung
10.2B
Branche
Biotechnologie
Land
United States
Handelsstatistiken
Durchschnittliches Volumen
2.62M
Börse
NMS
Währung
USD
52-Wochen-Spanne
Ähnliche Nachrichten
Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update
- Total Revenues of $597.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $542.9 million - - GAAP Diluted EPS of $0.69, Non-GAAP Diluted EPS of $0.78 - - Announced Additional Stock Repurchase Program for
Guggenheim Downgrades Exelixis to Neutral
Guggenheim analyst Michael W. Schmidt downgrades Exelixis from Buy to Neutral.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL). Such investors are...
Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its third quarter 2025 financial results will be released on Tuesday, November 4, 2025 after
Morgan Stanley Maintains Overweight on Exelixis, Lowers Price Target to $44
Morgan Stanley analyst Sean Laaman maintains Exelixis with a Overweight and lowers the price target from $50 to $44.
RBC Capital Reiterates Sector Perform on Exelixis, Maintains $45 Price Target
RBC Capital analyst Leonid Timashev reiterates Exelixis with a Sector Perform and maintains $45 price target.
Wells Fargo Maintains Equal-Weight on Exelixis, Lowers Price Target to $30
Wells Fargo analyst Derek Archila maintains Exelixis with a Equal-Weight and lowers the price target from $36 to $30.
Ähnliche Aktien
Bleiben Sie auf dem Laufenden
Preisalarme setzen, KI-Analyse-Updates und Echtzeit-Marktnachrichten erhalten.